Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7535 in type 2 diabetes mellitus inadequately controlled on metformin and SGLT2 inhibitor
CTR20241537Phase 2Completed
- Sponsor
- Shandong Shengdi Pharmaceutical
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-7535 in type 2 diabetes mellitus (T2DM), sponsored by Shandong Shengdi Pharmaceutical. Started May 2024; status: completed.
02
Drugs
HRS-7535
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20241537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241537.